Search
Showing results for "1"
News & Events
Telethon Institute research provides new insights into the cause of asthma attacksTelethon Institute for Child Health Research scientist Dr Anthony Bosco has been recognised for his cutting edge research investigating asthma attacks
Research
Innate immunity in human newborn infants: prematurity means more than immaturityNeonates, particularly those born prematurely, are exquisitely vulnerable to life-threatening infections. This increased susceptibility to infection...
The Clinical Research Manager will work in the Children's Diabetes Centre
The Children's Diabetes Centre is based at the Telethon Kids Institute and Princess Margaret Hospital (www.childrensdiabetescentre.org.au) and was
This project aims to examine whether maternal probiotic supplementation promotes an enhanced immunomodulatory breastmilk composition likely to promote infant oral tolerance, and reduce food allergy in breastfed children.
Research
Testing the meningococcal conjugate vaccine MenACWY-TT in toddlersJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Longitudinal Cognitive Performance in Individuals at Ultrahigh Risk for Psychosis: A 10-year Follow-upThe onset of psychosis was not associated with deterioration in cognitive ability
Research
Behavior in Children with Fetal Alcohol Spectrum Disorders in Remote Australia: A Population-Based StudyChildren with FASD have more teacher-reported behavioral impairment than children without FASD. In remote Australian communities, academic performance is poor.
Research
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 StudyDisease caused by Streptococcus pneumoniae is associated with considerable morbidity and mortality in children. Pneumococcal conjugate vaccines are well tolerated and effective at reducing pneumococcal disease caused by vaccine serotypes. VAXNEUVANCE (V114) is a 15-valent PCV containing 13 serotypes in Prevnar 13, plus serotypes 22F and 33F. This large phase 3 study evaluated safety and tolerability of V114 in infants.
Research
High prevalence of mgrB-mediated colistin resistance among carbapenem-resistant Klebsiella pneumoniae is associated with biofilm formation, and can be overcome by colistin-EDTA combination therapyThe global prevalence of colistin-resistant Klebsiella pneumoniae (ColRkp) facilitated by chromosomal and plasmid-mediated Ara4N or PEtN-remodeled LPS alterations has steadily increased with increased colistin usage for treating carbapenem-resistant K. pneumoniae (CRkp).